Page 100 - Read Online

Dixit et al. J Cancer Metastasis Treat 2022;8:47 https://dx.doi.org/10.20517/2394-4722.2022.70 Page 9 of 11

nanoparticles that are released from the SFH network can then preferentially enter cancer cells (because of
their proximity and cancer-targeting surface properties) to exert anticancer effects. Thus, more reports of
miRNAs related to MPM, especially those with tumor suppressor activity, are anticipated.

DECLARATIONS
Authors’ contributions
Conducted the article search, analyzed the data, and wrote the paper: Dixit S, Choi AY, Singh A, Hoang CD
Participated in the discussions about scope and articles included: Pittala K, Pruett N
Conceived the ideas, proposed the scope, supervised the project and revised the manuscript: Hoang CD

Availability of data and materials
Not applicable.

Financial support and sponsorship
This work was supported by NIH Intramural Research Program with funding (ZIA BC 011657) provided to
Chuong D. Hoang.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2022.

REFERENCES
1. Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug
Discov 2017;16:203-22. DOI PubMed
2. Shah MY, Ferrajoli A, Sood AK, Lopez-Berestein G, Calin GA. MicroRNA therapeutics in cancer - an emerging concept.
EBioMedicine 2016;12:34-42. DOI PubMed PMC
3. Network NCC. Malignant pleural mesothelioma (Version 1. 2022). Available from: https://www.nccn.org/professionals/physician_gls/
pdf/mpm.pdf [Last accessed on 2 Dec 2022].
4. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. Introduction to the 2015 world health organization classification of
tumors of the lung, pleura, thymus, and heart. J Thorac Oncol 2015;10:1240-2. DOI PubMed
5. Galateau-Salle F, Churg A, Roggli V, et al. The 2015 World Health Organization classification of tumors of the pleura: advances since
the 2004 classification. J Thorac Oncol 2016;11:142-54. DOI
6. Tsao AS, Pass HI, Rimner A, Mansfield AS. New era for malignant pleural mesothelioma: updates on therapeutic options. J Clin
Oncol 2022;40:681-92. DOI PubMed PMC
7. Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma
(CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 2021;397:375-86. DOI PubMed
8. Lo Russo G, Tessari A, Capece M, et al. MicroRNAs for the diagnosis and management of malignant pleural mesothelioma: a
literature review. Front Oncol 2018;8:650. DOI PubMed PMC
9. Fassina A, Cappellesso R, Guzzardo V, et al. Epithelial-mesenchymal transition in malignant mesothelioma. Mod Pathol 2012;25:86-
99. DOI
10. Pass HI, Goparaju C, Ivanov S, et al. hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma. Cancer Res
2010;70:1916-24. DOI PubMed PMC
11. Birnie KA, Yip YY, Ng DC, et al. Loss of miR-223 and JNK signaling contribute to elevated stathmin in malignant pleural
mesothelioma. Mol Cancer Res 2015;13:1106-18. DOI PubMed